TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth
Authors
Keywords
-
Journal
eLife
Volume 8, Issue -, Pages -
Publisher
eLife Sciences Publications, Ltd
Online
2019-12-19
DOI
10.7554/elife.47430
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Genomic correlates of clinical outcome in advanced prostate cancer
- (2019) Wassim Abida et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
- (2019) Kim N. Chi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular underpinnings of enzalutamide resistance
- (2018) Stefan Prekovic et al. ENDOCRINE-RELATED CANCER
- PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma
- (2018) Diede Brunen et al. MOLECULAR CANCER THERAPEUTICS
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer
- (2018) Aishwarya Pawar et al. Cell Reports
- Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis
- (2017) S Stelloo et al. ONCOGENE
- Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer
- (2017) Neel Shah et al. eLife
- TLE3 represses colorectal cancer proliferation by inhibiting MAPK and AKT signaling pathways
- (2016) Run-Wei Yang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide
- (2016) Stefan Prekovic et al. MOLECULAR CANCER THERAPEUTICS
- An interactive environment for agile analysis and visualization of ChIP-sequencing data
- (2016) Mads Lerdrup et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- An interactive environment for agile analysis and visualization of ChIP-sequencing data
- (2016) Mads Lerdrup et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The Groucho/Transducin-like enhancer of split protein family in animal development
- (2015) Megha Agarwal et al. IUBMB LIFE
- Improved vectors and genome-wide libraries for CRISPR screening
- (2014) Neville E Sanjana et al. NATURE METHODS
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The transcriptional co-repressor TLE3 suppresses basal signaling on a subset of estrogen receptor α target genes
- (2014) Maïka Jangal et al. NUCLEIC ACIDS RESEARCH
- Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool
- (2013) Edward Y Chen et al. BMC BIOINFORMATICS
- Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
- (2013) Vivek K. Arora et al. CELL
- Uniform, optimal signal processing of mapped deep-sequencing data
- (2013) Vibhor Kumar et al. NATURE BIOTECHNOLOGY
- An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
- (2013) M. Korpal et al. Cancer Discovery
- A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
- (2013) J. D. Joseph et al. Cancer Discovery
- Overcoming mutation-based resistance to antiandrogens with rational drug design
- (2013) Minna D Balbas et al. eLife
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- FoxA1 Specifies Unique Androgen and Glucocorticoid Receptor Binding Events in Prostate Cancer Cells
- (2012) B. Sahu et al. CANCER RESEARCH
- Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines
- (2012) Y. Li et al. CANCER RESEARCH
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis
- (2011) Charles E Massie et al. EMBO JOURNAL
- Integrative Genomic Profiling of Human Prostate Cancer
- (2010) Barry S. Taylor et al. CANCER CELL
- seqMINER: an integrated ChIP-seq data interpretation platform
- (2010) Tao Ye et al. NUCLEIC ACIDS RESEARCH
- Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer
- (2009) J Mullenders et al. ONCOGENE
- Context-dependent regulation of Groucho/TLE-mediated repression
- (2008) Einat Cinnamon et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Model-based Analysis of ChIP-Seq (MACS)
- (2008) Yong Zhang et al. GENOME BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More